Environmental toxicants such as perfluorooctanesulfonate (PFOS) have been implicated in male reproductive dysfunction, including reduced sperm count and semen quality, in humans. However, the underlying mechanism(s) remains unknown. Herein PFOS at 10-20 μM (∼5-10 μg/mL) was found to be more potent than bisphenol A (100 μM) in perturbing the blood-testis barrier (BTB) function by disrupting the Sertoli cell tight junction-permeability barrier without detectable cytotoxicity. We also delineated the underlying molecular mechanism by which PFOS perturbed Sertoli cell BTB function using an in vitro model that mimics the BTB in vivo. First, PFOS perturbed F-actin organization in Sertoli cells, causing truncation of actin filaments at the BTB. Thus, the actin-based cytoskeleton was no longer capable of supporting the distribution and/or localization of actin-regulatory and adhesion proteins at the cell-cell interface necessary to maintain BTB integrity. Second, PFOS was found to perturb inter-Sertoli cell gap junction (GJ) communication based on a dye-transfer assay by down-regulating the expression of connexin-43, a GJ integral membrane protein. Third, phosphorylated focal adhesion kinase (FAK)-Tyr(407) was found to protect the BTB from the destructive effects of PFOS as shown in a study via an overexpression of an FAK Y407E phosphomimetic mutant. Also, transfection of Sertoli cells with an FAK-specific microRNA, miR-135b, to knock down the expression of phosphorylated FAK-Tyr(407) was found to worsen PFOS-mediated Sertoli cell tight junction disruption. In summary, PFOS-induced BTB disruption is mediated by down-regulating phosphorylated FAK-Tyr(407) and connexin-43, which in turn perturbed F-actin organization and GJ-based intercellular communication, leading to mislocalization of actin-regulatory and adhesion proteins at the BTB.
Pubmed ID: 24169556 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal targets ACTG1, ACTC1, ACTA1, ACTA2, ACTG2, ACTB
View all literature mentionsThis unknown targets Mouse IgG (H+L)
View all literature mentionsThis monoclonal targets Filamin A antibody [FLMN01] - BSA and Azide free
View all literature mentionsThis polyclonal targets Palladin
View all literature mentionsThis monoclonal targets FAK
View all literature mentionsThis polyclonal targets Connexin 43
View all literature mentionsThis monoclonal targets N-cadherin
View all literature mentionsThis monoclonal targets ZO-1
View all literature mentionsThis unknown targets JAM-A (CD321)
View all literature mentionsThis unknown targets Phospho-FAK (Tyr407)
View all literature mentionsThis unknown targets ZO-1
View all literature mentionsThis unknown targets Occludin
View all literature mentionsThis unknown targets beta Catenin
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal targets FAK (phospho Y397) antibody
View all literature mentionsThis polyclonal targets FAK
View all literature mentionsThis monoclonal targets ARP3
View all literature mentionsThis monoclonal targets Vimentin (V9)
View all literature mentionsThis polyclonal targets Goat IgG
View all literature mentionsThis polyclonal targets bovine anti-mouse IgG-HRP
View all literature mentionsThis polyclonal targets Rabbit IgG
View all literature mentionsThis polyclonal targets CDH2
View all literature mentions